Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 4.8% - Here's What Happened

Tango Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Tango Therapeutics shares rose 4.8% to $22.93 in Thursday mid-day trading, while trading volume was about 95% below its average.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $48.17; recent targets ranged from $40 to $67.
  • The company reported a quarterly loss of $0.39 per share, missing the $0.35 loss analysts expected. Insiders also sold a combined 52,231 shares over the past 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) shares traded up 4.8% during mid-day trading on Thursday. The company traded as high as $23.66 and last traded at $22.93. Approximately 190,095 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 3,458,693 shares. The stock had previously closed at $21.89.

Analyst Ratings Changes

Several research firms recently issued reports on TNGX. Wedbush cut their price objective on shares of Tango Therapeutics from $45.00 to $40.00 and set an "outperform" rating for the company in a research report on Tuesday, November 10th. Wall Street Zen cut shares of Tango Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Stifel Nicolaus set a $55.00 price target on shares of Tango Therapeutics in a report on Friday, October 23rd. JPMorgan Chase & Co. lifted their price target on shares of Tango Therapeutics from $46.00 to $47.00 and gave the company an "overweight" rating in a research report on Tuesday, November 10th. Finally, HC Wainwright reduced their price target on shares of Tango Therapeutics from $68.00 to $67.00 and set a "buy" rating on the stock in a research report on Tuesday, November 10th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $48.17.

Read Our Latest Report on Tango Therapeutics

Tango Therapeutics Trading Up 5.1%

The firm's fifty day moving average is $23.51 and its 200-day moving average is $22.96. The stock has a market capitalization of $3.90 billion, a PE ratio of -16.78 and a beta of 1.26.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). As a group, equities analysts predict that Tango Therapeutics, Inc. will post -1.47 EPS for the current year.

Insider Buying and Selling

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the sale, the insider owned 115,743 shares of the company's stock, valued at $2,832,231.21. The trade was a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jessica Newcomb sold 8,200 shares of the company's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total value of $198,604.00. Following the transaction, the insider owned 59,121 shares in the company, valued at $1,431,910.62. This trade represents a 12.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 52,231 shares of company stock valued at $1,254,029 in the last ninety days. 6.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Tango Therapeutics by 4.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 13,734 shares of the company's stock valued at $336,000 after buying an additional 534 shares during the period. Allworth Financial LP grew its position in shares of Tango Therapeutics by 100.9% during the second quarter. Allworth Financial LP now owns 1,131 shares of the company's stock worth $35,000 after buying an additional 568 shares in the last quarter. Nykredit A S purchased a new stake in shares of Tango Therapeutics during the second quarter worth approximately $26,000. Bleakley Financial Group LLC increased its stake in shares of Tango Therapeutics by 7.0% during the third quarter. Bleakley Financial Group LLC now owns 13,162 shares of the company's stock worth $328,000 after buying an additional 860 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Tango Therapeutics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company's stock valued at $10,237,000 after acquiring an additional 2,272 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company's stock.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tango Therapeutics Right Now?

Before you consider Tango Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.

While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines